Gabriel KornMar 5, 20201 min readTargeted Therapy: Rapid Advances Change the Paradigm in Bladder Cancer A greater understanding of not only tumor biology and driver mutations but also targeted therapy has led to unprecedented precision and efficacy in treating bladder cancer.FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinomaFDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancerRead More
A greater understanding of not only tumor biology and driver mutations but also targeted therapy has led to unprecedented precision and efficacy in treating bladder cancer.FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinomaFDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancerRead More
Комментарии